Moderna, Inc. (NASDAQ:MRNA – Get Free Report)’s stock price traded up 4.9% during mid-day trading on Friday. The company traded as high as $209.48 and last traded at $209.1080. Approximately 1,417,480 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 12,430,554 shares. The stock had previously closed at $199.33.
Key Stories Impacting Moderna
Here are a few of the latest stories about MRNA:
- Negative Sentiment: Investors are concerned that Moderna’s 2027 cash costs could reach $4 billion. The spending burden, alongside uncertain revenue from its expanding vaccine and oncology pipeline, raises questions about funding its next phase of growth. Article: Moderna's 2027 Cash Costs
- Negative Sentiment: President Stephen Hoge sold shares in transactions reported for November 16 and 17, and coverage noted the stock fell below its 50-day moving average. The sales were made under a pre-arranged Rule 10b5-1 plan, so they do not necessarily signal a change in his view of the company, but they may add to near-term selling pressure. Article: Moderna President Sells Shares
- Neutral Sentiment: Bireme Capital disclosed that it sold its Moderna position after the stock’s rally. That reflects one manager’s portfolio decision, rather than a company announcement. Article: Bireme Capital Sold Moderna
Analyst Ratings Changes
Several brokerages recently weighed in on MRNA. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Friday, August 28th. Morgan Stanley lifted their price objective on shares of Moderna from $95.00 to $200.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 17th. William Blair downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Finally, Bank of America boosted their price objective on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $120.25.
Moderna Stock Performance
The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The stock has a fifty day moving average price of $207.87 and a two-hundred day moving average price of $100.37. The company has a market cap of $78.57 billion, a P/E ratio of -27.35 and a beta of 1.16.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same period in the prior year, the company posted ($0.51) EPS. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -5.23 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares in the company, valued at $219,921,913.54. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 275,626 shares of company stock worth $50,776,076. 10.80% of the stock is owned by company insiders.
Institutional Trading of Moderna
A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. American Century Companies Inc. lifted its stake in shares of Moderna by 101.1% in the 3rd quarter. American Century Companies Inc. now owns 222,918 shares of the company’s stock worth $42,927,000 after acquiring an additional 112,058 shares during the period. Cim Investment Management Inc. acquired a new position in shares of Moderna during the third quarter valued at approximately $290,000. PCM Encore LLC increased its stake in shares of Moderna by 24.6% during the third quarter. PCM Encore LLC now owns 3,944 shares of the company’s stock valued at $760,000 after acquiring an additional 779 shares during the period. First National Bank of Hutchinson acquired a new position in shares of Moderna during the third quarter valued at approximately $597,000. Finally, Defiance ETFs LLC bought a new stake in Moderna during the third quarter worth approximately $517,000. 75.33% of the stock is currently owned by institutional investors.
About Moderna
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Recommended Stories
- Five stocks we like better than Moderna
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
